MEITHEAL
LIVE

Serial Number

99917615

Owner

Meitheal Pharmaceuticals, Inc.

Attorney

Eric R. Moran

Filing Date

Jul 1, 2026

Add to watchlist:

No watchlists yet
View on USPTO

MEITHEAL Trademark

Serial Number: 99917615

MEITHEAL is a trademark filed by Meitheal Pharmaceuticals, Inc. on July 1, 2026. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Meitheal Pharmaceuticals, Inc. (15 trademarks)

Chicago, IL 60631

Entity Type: 03

Trademark Details

Filing Date

July 1, 2026

Registration Date

Not Registered

Goods & Services

House mark for a full line of pharmaceutical preparations; pharmaceutical preparations for treating vitamin deficiency; vitamin analogs; pharmaceutical preparations for treating vitamin B12 deficiency; vitamin B12 analogs; pharmaceutical preparations for treating vitamin B9 deficiency; vitamin B9 analogs; pharmaceutical preparations for treating anemia; pharmaceutical preparations for treating vitamin B1 deficiency; vitamin B1 analogs; diuretics; diuretic preparations; pharmaceutical preparations, namely, diuretics; pharmaceutical preparations for enhancing fertility; pharmaceutical antipsychotic preparations; pharmaceutical preparations for the treatment of psychotic disorders; pharmaceutical preparations for increasing GLP-1 levels; GLP-1 receptor agonists for treating diabetes and obesity; methylene blue to treat methemoglobinemia for medical use; dye used in medical, pharmaceutical and veterinary substances; dietetic substances for medical or veterinary purposes, namely, dietary supplements containing methylene blue, in the form of tablets or capsules, or liquid form; antifungal preparations; pharmaceutical preparations, namely, antifungal preparations; pharmaceutical preparations for treating multiple sclerosis; pharmaceutical preparations for treating neurological diseases and disorders; pharmaceutical products for treating autoimmune diseases and disorders; injectable pharmaceutical preparations for treating multiple sclerosis; syringes sold filled with injectable pharmaceutical preparations for treating multiple sclerosis; immunostimulant preparations; pharmaceutical preparations, namely, immunostimulants for increasing white blood cell production; pharmaceutical preparations for treating Paget's disease; pharmaceutical preparations for the prevention and treatment of disorders of the musculoskeletal system, namely, osteoporosis, Paget's disease, and other bone-related diseases and disorders; pharmaceutical preparations for treating osteoporosis; pharmaceutical preparations for treating and preventing hypoglycemia; Pharmaceutical preparations, namely, glucagon for diabetes related hypoglycemia, including low blood sugar, diabetes insulin shock, and insulin reaction; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for glycemic control; pharmaceutical preparations for treating systemic inflammatory conditions; pharmaceutical preparations, namely, corticosteroids

Filing History

TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Jul 1, 2026 TAEA
TEAS VOLUNTARY AMENDMENT RECEIVED
Jul 1, 2026 PARI
APPLICATION FILING RECEIPT MAILED
Jul 1, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 1, 2026 NWOS
NEW APPLICATION ENTERED
Jul 1, 2026 NWAP